Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.

Autonomic neuroscience : basic & clinical - 1 Apr 2026

Chen Shuai, Shen Yu, Shao Jingyu, Li Rong, Hao Xiaodi, Yang Hongqi, Ma Kai, Zhang Jiewen

Abstract excerpt

The pathophysiological biomarkers underlying the progression of autonomic dysfunction in Parkinson's disease (PD) are not fully understood. We conducted a cohort analysis of 116 sporadic PD patients to determine whether CSF concentrations of total LRRK2 protein and its phosphorylated substrate p-Rab10 predict the trajectories of SCOPA-AUT scores over five years. CSF LRRK2 and p-Rab10 were similarly elevated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Autonomic Nervous System Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Cohort Studies

Share to Disease Progression

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Mutation

Share to Parkinson Disease

Source

Identifiers

PMID: 41762849
DOI: 10.1016/j.autneu.2026.103399

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.PMID 41762849Read ↗

Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.Semantic proximity Read ↗

LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationSemantic proximity Read ↗

LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.Semantic proximity Read ↗

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.Semantic proximity Read ↗

Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.Semantic proximity Read ↗

LRRK2-Associated Parkinsonism With and Without<i>In Vivo</i>Evidence of Alpha-Synuclein AggregatesSemantic proximity Read ↗

Progression in the LRRK2-Asssociated Parkinson Disease Population.Semantic proximity Read ↗

Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical DataSemantic proximity Read ↗

Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriersSemantic proximity Read ↗

Autonomic dysfunction in genetic forms of synucleinopathies.Semantic proximity Read ↗

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.Semantic proximity Read ↗

Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.